Eli Lilly’s weight-loss drug cuts diabetes risk by 94% in three-year trial, ET HealthWorld

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

Eli Lilly’s weight-loss ***** cuts diabetes risk by 94% in three-year trial, ET HealthWorld

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

London: Eli Lilly’s weight-loss ***** cut the risk of developing type 2 diabetes by 94 per cent in pre-diabetic adults who were overweight or obese after three years of weekly injections, the company disclosed in a statement on Tuesday.

The Indianapolis, Indiana-based company said the data comes from the longest completed trial of the *****, and reinforces the long-term benefits of tirzepatide – the chemical name of its Zepbound and Mounjaro treatments.

“We just don’t see numbers like this in metabolic space,” said BMO Capital Markets analyst Evan Seigerman. He added that Novo’s ***** had also showed a 73 per cent risk reduction after three years in a separate late-stage trial.

Both Eli Lilly and rival Novo Nordisk have been pushing to extend the use of their obesity drugs to related conditions, which would help expand the patient pool and gain wider insurance coverage.

Shares of Eli Lilly rose 2.2 per cent to $942 in premarket trading.

Lilly’s data comes amid concerns that patients reduce the use of weight-loss drugs over time.

Reuters reported in July that only one in four U.S. patients prescribed Novo’s Wegovy or Ozempic for weight loss two years ago were still taking the popular medications.

Early results from its late-stage trial, “SURMOUNT-1”, were initially disclosed in 2022. The data at that time, which showed the ***** helped significantly cut weight in obese patients, helped it secure U.S. regulatory approval.

In the trial involving 1,032 adults, patients who received weekly injections showed a 94 per cent reduction in the risk of progression to type 2 diabetes compared to placebo.

Treatment with the highest dose of tirzepatide resulted in an average weight reduction of 22.9 per cent , compared to just 2.1 per cent for the placebo, Lilly said.

(Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli and Tasim Zahid)

• Published On Aug 20, 2024 at 06:36 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Download ETHealthworld App

• Get Realtime updates
• Save your favourite articles

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Scan to download App
data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

This is the hidden content, please

• Sign In
• or
• Sign Up

#Eli #Lillys #weightloss #***** #cuts #diabetes #risk #threeyear #trial #HealthWorld

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up